

A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight

NCT07441252

Status	RECRUITING
Phase	Phase 2
Sponsor	Amgen
Enrollment	180 participants

Key Eligibility Criteria

Inclusion (9)

- Age \geq 18 years.
 - Body Mass index (BMI) \geq 27 kg/m² to \leq 40 kg/m² at screening.
 - For participants with type 2 diabetes mellitus (T2DM) at screening:
 - HbA1c \leq 9.5% (80 mmol/mol) at screening.
 - Treated with diet and exercise alone and/or a stable treatment with metformin, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, or combination.
- ... and 4 more (see full listing online)

Exclusion (13)

- Recent or planned surgical/device-based obesity treatment ($<$ 1 year).
 - History of malignancy within the past 5 years (exceptions apply).
 - Type 1 diabetes or non-type 2 diabetes mellitus (T2DM); unstable/severe hypoglycemia.
 - Advanced diabetic retinopathy or macular edema.
 - History of pancreatitis (acute $<$ 180 days or chronic).
- ... and 8 more (see full listing online)

Locations (10 total)

Arizona Clinical Trials, Chandler, Arizona, United States
Medical Advancement Centers of Arizona, Phoenix, Arizona, United States
Indago Research and Health Center, Hialeah, Florida, United States
... and 7 more locations